Research programme: bispecific antibody therapeutics - Merus/Selexis
Latest Information Update: 22 Nov 2016
At a glance
- Originator Merus; Selexis
- Class Bispecific antibodies
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer